Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals & M&A

Set Alert for Deals & M&A

Ipsen Targets External Innovation With Exicure Option In Rare Neurodegenerative Disorders

France’s Ipsen has taken an exclusive option on two neurodegenerative disease programs at US biotech Exicure, whose oligonucleotide nanoparticles are taken up by many tissues, including the brain.

Rare Diseases Neurology

Sanofi Goes All The Way In mRNA With Translate Bio Buy

Taking full control of partner Translate Bio means that Sanofi is the only big vaccine company with a wholly-owned mRNA platform in-house but observers say it is too early to declare that the Paris-headquartered group has bagged itself a bargain.

M & A Vaccines

Canadian Biotech Takes COVID-19 Nasal Spray To Asia Via Glenmark

Glenmark hopes to launch SaNOtize’s nitric oxide nasal spray for COVID-19 in India by the fourth quarter of 2021 post Phase III trials, as part of wider deal that covers other Asian markets. Can the self-administered product impact market dynamics positioned as the first line of defense against COVID-19?

Commercial Coronavirus COVID-19

Takeda Takes Alliance Route For Norovirus Vaccine

Japanese firm again links with an earlier venture capital partner and some familiar faces to progress its norovirus vaccine outside Japan.

Deals Vaccines

Dawn Of A New Era? Korean Biopharma M&A Landscape Set For Change

Mergers and acquisitions are set to gain momentum in South Korea as firms outside the sector seek new growth engines and more open-minded biopharma companies seek rapid growth and globalization.

South Korea M & A

Merck & Co. CEO Davis Debuts With A Leaner Organization And Money To Spend

Merck's new CEO Robert Davis talked about his vision for business development and how the company might use the $9bn gained from the spinout of Organon.

Sales & Earnings Deals

Ipsen Buys Into BAX Inhibitor, Targeting Certain Cancers

Ipsen has inked a worldwide collaboration pact with BAKX Therapeutics to research, develop, manufacture and commercialize the biotech’s asset BKX-001 as a potential treatment for leukemia, lymphoma and solid tumors.

Clinical Trials Commercial

Amgen Builds Out Antibody Interests With $2.5bn Teneobio Buy

Private California venture will bring additional expertise and novel platforms to acquisitive biotech giant as it looks to expand its interests in bispecific and multispecific antibody technologies.

Companies M & A

Organon's First Move Post Spinout Is A Licensing Deal With ObsEva In Preterm Labor

Ogranon will pay $25m upfront for worldwide commercialization rights to ebopiprant for acute preterm labor, which currently has no approved treatments in the US.

Gynecology & Urology Deals

AC Immune Beefs Up Neurodegenerative Pipeline With AFFiRiS Alpha-Synuclein Portfolio

Deal Snapshot: The company is looking to expand its pipeline beyond Alzheimer’s, where it hit a speedbump in September with the failure of a tau-targeting drug.

Deals Research and Development Strategies

Asia Deal Watch: GC Pharma Looks To Build On Enzyme Replacement Therapy Success

South Korean firm teams with Speragen to develop enzyme-replacement therapy for the genetic disorder and with Mirum for maralixibat. Plus deals involving Takeda/PeptiDream, Hanmi/LegoChem, Sun/Cassiopea, LegoChem/Cellectar, ChubLab/CJ CheilJedang Corp., Alebund/Chugai, Kintor/Fosun, Astellas/ExCellThera and I-Mab/neoX/Immorna.

Deal Watch Asia Pacific

Arvinas, Pfizer Partner To Pursue Best-In-Class Breast Cancer Strategy

Pfizer agreed to pay up to $2.4bn to share development and commercialization costs for Arvinas’ estrogen receptor degrader, including in combination with Ibrance.

Deals Cancer
UsernamePublicRestriction

Register